Ya-Han-Lu-Duan decoction reshapes tumor microenvironment to treat colitis-associated colorectal cancer by regulating arachidonic acid metabolism

Figure 1 Ya-Han-Lu-Duan treatment alleviates pathology in colitis-associated colorectal cancer mice. A: Establishment of the colitis-associated colorectal cancer mouse model and timeline of drug administration; B: Survival curves of mice in each group; C: Weekly body weight changes in each group of mice; D: Colon lengths in each group of mice; E: Tumor counts in each group of mice; F: Tumor burden in each group of mice; G: Representative hematoxylin and eosin staining of colon tissue sections from each group of mice. n = 20 in control group, n = 12 in colitis-associated colorectal cancer group, n = 18 in sulfasalazine group, n = 13 in low-dose Ya-Han-Lu-Duan (YHLD) group, n = 15 in medium-dose YHLD group, n = 18 in high-dose YHLD group for panel (B-G). Data are presented as the mean ± SD. ^aP < 0.05, ^bP < 0.01. CAC: Colitis-associated colorectal cancer; AOM: Azoxymethane; DSS: Dextran sulfate sodium; CON: Control; SASP: Sulfasalazine; YHLD-H: High-dose Ya-Han-Lu-Duan; YHLD-L: Low-dose Ya-Han-Lu-Duan; YHLD-M: Medium-dose Ya-Han-Lu-Duan; HE: Hematoxylin and eosin.